The impact of antiretroviral therapy on mortality in hiv positive people during tuberculosis treatment: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Odone, Anna ^a,b,c   Amadasi, Silvia ^d   White, Richard G ^a   Cohen, Theodore ^e,f   Grant, Alison D ^a   Houben, Rein M G J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; BIOINFORMATICS; CLINICAL ASSESSMENT TOOL; DATA ANALYSIS; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH IMPACT ASSESSMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; META ANALYSIS; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TUBERCULOSIS; TUBERCULOSIS CASE FATALITY RATIO; COMORBIDITY; COMPLICATION; HIV INFECTIONS; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTI-RETROVIRAL AGENTS; COMORBIDITY; DATA INTERPRETATION, STATISTICAL; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84911467943     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112017     Document Type: Review

References (60)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
2. WHO (2013) Global Tuberculosis Report 2013. Geneva: World Health Organisation.
3. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, et al. (2012) Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 9: e1001270.
4. Curran A, Falco V, Pahissa A, Ribera E (2012) Management of tuberculosis in HIV-infected patients. AIDS Rev 14: 231-246.
5. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. New England Journal of Medicine 362: 697-706.
6. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal of Medicine 365: 1471-1481.
7. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365: 1482-1491.
8. Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, et al. (2012) Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 60: 377-383.
9. Torok ME, Yen NT, Chau TT, Mai NT, Phu NH, et al. (2011) Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)- associated tuberculous meningitis. Clin Infect Dis 52: 1374-1383.
10. Boulle A, Clayden P, Cohen K, Cohen T, Conradie F, et al. (2010) Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J 100: 566, 568, 570-561.
11. Laureillard D, Marcy O, Madec Y, Chea S, Chan S, et al. (2013) Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 27: 2577-2586.
12. Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ (2011) Assessing tuberculosis case fatality ratio: A meta-analysis. PLoS One 6.
13. Glaziou P, Floyd K, Raviglione M (2009) Global burden and epidemiology of tuberculosis. Clin Chest Med 30: 621-636, vii.
14. Gandhi NR, Moll AP, Lalloo U, Pawinski R, Zeller K, et al. (2009) Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 50: 37-43.
15. Mukadi YD, Maher D, Harries A (2001) Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 15: 143-152.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8: 336-341.
17. Lim MS, Dowdeswell RJ, Murray J, Field N, Glynn JR, et al. (2012) The impact of HIV, an antiretroviral programme and tuberculosis on mortality in South African platinum miners, 1992-2010. PLoS One 7: e38598.
18. Davies NE, Karstaedt AS (2012) Antiretroviral outcomes in South African prisoners: a retrospective cohort analysis. PLoS One 7: e33309.
19. Casas EC, Decroo T, Mahoudo JA, Baltazar JM, Dores CD, et al. (2011) Burden and outcome of HIV infection and other morbidities in health care workers attending an Occupational Health Program at the Provincial Hospital of Tete, Mozambique. Trop Med Int Health 16: 1450-1456.
20. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH (2010) Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 376: 367-387.
21. Higgins JP, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], 5.1.0 ed. The Cochrane Collaboration.
22. Wells G (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/ programs/clinical-epidemiology/oxford.asp. Accessed 2014 Oct 23.
23. Agodokpessi G, Ade G, Ade S, Wachinou AP, Affolabi D, et al. (2012) Management of tuberculosis and HIV co-infection in Cotonou, Benin. Med Mal Infect 42: 561-566.
24. Henegar CE, Behets F, Vanden Driessche K, Tabala M, Bahati E, et al. (2012) Mortality among tuberculosis patients in the Democratic Republic of Congo. International Journal of Tuberculosis and Lung Disease 16: 1199-1204.
25. Kendon M, Knight SE, Ross A, Giddy J (2012) Timing of antiretroviral therapy initiation in adults with HIV-associated tuberculosis: Outcomes of therapy in an urban hospital in KwaZulu-Natal. South African Medical Journal 102: 931-935.
26. Nansera D, Bajunirwe F, Elyanu P, Asiimwe C, Amanyire G, et al. (2012) Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda. International Journal of Tuberculosis and Lung Disease 16: 1371-1376.
27. Zachariah R, Fitzgerald M, Massaquoi M, Acabu A, Chilomo D, et al. (2007) Does antiretroviral treatment reduce case fatality among HIV-positive patients with tuberculosis in Malawi? Int J Tuberc Lung Dis 11: 848-853.
28. Ferroussier O, Dlodlo RA, Capo-Chichi D, Boillot F, Gninafon M, et al. (2013) Results of rapid and successful integration of HIV diagnosis and care into tuberculosis services in Benin. International Journal of Tuberculosis and Lung Disease 17 (11): 1405-1410.
29. Kaplan R, Caldwell J, Middelkoop K, Bekker LG, Wood R (2014) Impact of ART on TB Case Fatality Stratified by CD4 Count for HIV-Positive TB Patients in Cape Town, South Africa (2009-2011). J Acquir Immune Defic Syndr 66: 487-494.
30. Kayigamba FR, Bakker MI, Mugisha V, de Naeyer L, Gasana M, et al. (2013) Adherence to Tuberculosis Treatment, Sputum Smear Conversion and Mortality: A Retrospective Cohort Study in 48 Rwandan Clinics. PLoS ONE 8 (9).
31. Sileshi B, Deyessa N, Girma B, Melese M, Suarez P (2013) Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: A retrospective cohort study. BMC Infectious Diseases 13 (1).
32. Tweya H, Feldacker C, Phiri S, Ben-Smith A, Fenner L, et al. (2013) Comparison of treatment outcomes of new smear-positive pulmonary tuberculosis patients by HIV and antiretroviral status in a TB/HIV clinic, Malawi. PLoS ONE 8 (2).
33. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D, Monkongdee P, et al. (2007) Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 13: 1001-1007.
34. Raizada N, Chauhan LS, Babu BS, Thakur R, Khera A, et al. (2009) Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India. PLoS One 4.
35. Sanguanwongse N, Cain KP, Suriya P, Nateniyom S, Yamada N, et al. (2008) Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 48: 181-189.
36. Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, et al. (2012) Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis 12.
37. Tansuphasawadikul S, Saito W, Kim J, Phonrat B, Dhitavat J, et al. (2007) Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Public Health 38: 1053-1060.
38. Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, et al. (2009) HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis 9: 42.
39. Zhao H, Chen YMA, Lee C, Omar SFS, Phanuphak N, et al. (2014) Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: Results from the TREAT Asia HIV Observational Database. HIV Medicine 15 (2): 77-85.
40. Dos Santos APG, Pacheco AG, Staviack A, Golub JE, Chaisson RE, et al. (2013) Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil. International Journal of Tuberculosis and Lung Disease 17: 192-197 +i.
41. Schmaltz CA, Sant'Anna FM, Neves SC, Velasque Lde S, Lourenco MC, et al. (2009) Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 52: 623-628.
42. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16: 75-83.
43. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362: 697-706.
44. Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, et al. (2014) Early versus delayed initiation of highly active antiretroviral therapy for HIVpositive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 14: 563-571.
45. Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, et al. (2012) Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis 12: 168.
46. Walpola HC, Siskind V, Patel AM, Konstantinos A, Derhy P (2003) Tuberculosis-related deaths in Queensland, Australia, 1989-1998: characteristics and risk factors. Int J Tuberc Lung Dis 7: 742-750.
47. Dheda K, Lampe FC, Johnson MA, Lipman MC (2004) Outcome of HIVassociated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 190: 1670-1676.
48. Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R (2013) Management of HIV-associated tuberculosis in resource-limited settings: A state-of-the-art review. BMC Medicine 11 (1).
49. Doherty M, Ford N, Vitoria M, Weiler G, Hirnschall G (2013) The 2013 WHO guidelines for antiretroviral therapy: Evidence-based recommendations to face new epidemic realities. Current Opinion in HIV and AIDS 8 (6): 528-534.
50. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 1492-1501.
51. th ed. 2010 (WHO/HTM/TB/2009.420) Available: http://whqlibdoc.who.int/ publications/2010/9789241547833-eng.pdf?ua=1. Accessed August 14, 2014.
52. TB CARE I (2014) International Standards for Tuberculosis Care, Edition 3. TB CARE I, The Hague. Available: http://www.thoracic.org/assemblies/ mtpi/resources/istc-report.pdf. Accessed August 14, 2014.
53. Panel on Antiretroviral Guidelines for Adults and Adolescents (2013) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed August 14, 2014.
54. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402.
55. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2013. Available: www.who.int/hiv/pub/guidelines/arv2013. Accessed August 14, 2014.
56. The Lancet Global Heath Blog (2013) Clinical trials and global health equity. Available: http://globalhealth.thelancet.com/2013/07/08/clinical-trials-and-global- health-equity. Accessed October 23, 2014.
57. Korenromp EL, Bierrenbach AL, Williams BG, Dye C (2009) The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 13: 283-303.
58. The Stop TB Partnership (2014) WHA approves Post-2015 Global Strategy and Targets For Tuberculosis Prevention, Care and Control. Available: http://www. stoptb.org/news/stories/2014/ns14-031.asp. Accessed October 23, 2014.
59. Legido-Quigley H, Montgomery CM, Khan P, Atun R, Fakoya A, et al. (2013) Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health 18: 199-211.
60. Oxford Centre for Evidence-Based Medicine website. Available: http://www. cebm.net/ocebm-levels-of-evidence/. Accessed October 23, 2014.